Detection of mesothelioma and pancreatic cancer earlier, thanks to the new biomarkers identified by SomaLogic in Boulder, Colorado in a hurry, you may. Considering the current difficulties in the treatment of disease diagnosis and both of these, and among the medical community is met with much enthusiasm and discovery.
SomaLogic team earlier mesothelioma enlarged part of the study (led by Dr. Rachel Ostrov) from Mesothelioma and lung cancer and diagnose patients have investigated the serum samples collected 357. Samples collected from personal harm lung disease, risk high smokers and subjects were exposed to the previous asbestos control as we compare samples. Were subjected to all sample aptamer-based Proteomics array technology.
7 Important table indicated as a team when comparing successful mesothelioma tumor biomarkers discovery. Using these biomarkers SomaLogic staff [13 plex random forest Classifier "in diagnosing mesothelioma myeloma patients all" setting blind tests incorporated in an effort. Ability to identify the subjects of mesothelioma from asbestos public patient researchers reports 100% specificity and sensitivity of 80%.
For the part of the study of pancreatic cancer, we used model of the team, the same technology and research. Sample, diagnosed with pancreatic cancer and 116 compared to control sample 143 were drawn from a patient. We 25% blind samples from both the Group of validation at parse time. Based on the follow-up of these blind 65% of 96.5% specificity and sensitivity report team. Additional test took into account patient symptoms, the 90% and 75% of the sensitivity specificity has been improved.
It is common to mesothelioma and pancreatic cancer diagnostic phase. Statistics shows that approximately 20% of pancreatic cancer patients to survive more than a year after the date of diagnosis. At the time of diagnosis is more than 90% of the patient's tumor surgical options has progressed beyond points. To survive beyond the mark 1, mesothelioma myeloma patients and patient some statistical information is confirmed.
According to the Ostrov "identification may improve quality of life and survival of their early detection of these aggressive cancers early stage patient treatment. ?
Development of a new discovery cancer research meeting molecular diagnostic cancer treatment at United States Association, is announced. From 27 September meeting 30 was held in Denver.
No comments:
Post a Comment